NCT03602508

Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 5,589 (actual)
• Sponsor: Astellas Pharma Singapore Pte. Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to descriptively evaluate the persistence among adults treated with mirabegron or antimuscarinics in Australia, South Korea and Taiwan. This study will also assess the persistence to the overall Overactive bladder (OAB) treatments of a patient, regardless of treatment discontinuation or switch to other OAB medications.

Detailed description

This study is entirely descriptive using secondary medical claim and pharmacy prescription data. No formal comparisons between users of mirabegron and antimuscarinic will be made. Furthermore, no a priori hypothesis testing is intended.

Conditions

• Overactive Bladder (OAB)

Interventions

Type	Name	Description
DRUG	mirabegron	oral
DRUG	solifenacin	oral
DRUG	darifenacin	oral
DRUG	imidafenacin	oral
DRUG	tolterodine	oral
DRUG	oxybutynin	oral
DRUG	trospium	oral
DRUG	fesoterodine	oral
DRUG	propiverine	oral

Timeline

• Start date: 2018-07-20
• Primary completion: 2019-09-13
• Completion: 2019-09-13
• First posted: 2018-07-27
• Last updated: 2024-10-16

Locations

2 sites across 2 countries: Australia, South Korea